| Literature DB >> 22146768 |
Jenny M Whitworth1, J Michael Straughn, Venkatram R Atigadda, Donald D Muccio, Donald J Buchsbaum.
Abstract
Ovarian cancer is the deadliest of all gynecologic malignancies. The search for novel treatment modalities to augment traditional chemotherapy and improve quality of life is ongoing. Retinoids, a class of compounds composed of vitamin A, its natural derivatives, and synthetic analogs, have been studied extensively in both the prevention and treatment of gynecologic malignancies. In this article, we reviewed preclinical studies and clinical trials conducted using retinoids in ovarian cancer.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22146768 DOI: 10.1097/IGC.0b013e318236a2ec
Source DB: PubMed Journal: Int J Gynecol Cancer ISSN: 1048-891X Impact factor: 3.437